Project Grant HT9425261E244
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $499K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- Federal Project Grant Award Summary The University of Washington received a $499,551 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2028. The research project, titled "Enhancing Muscle Stem Cell Targeting to Improve Durability of Genome Editing Therapies for DMD," focuses on developing advanced therapeutic approaches for Duchenne muscular dystrophy (DMD) through...
- The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University's Office of Sponsored Research Services a $834,915 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period May 1, 2026 through April 30, 2028. The grant supports the development of small molecule therapeutic candidates designed to disrupt TDP-43 (TAR DNA-binding protein 43) aggregation and restore protein function. This research addresses...
- Federal Grant Award Summary The University of Washington received a $1.49 million project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop biomaterial strategies improving the specificity and efficacy of chimeric antigen receptor T (CAR-T) cell therapy for breast cancer treatment. The three-year award, effective April 1, 2026 through March 31, 2029, supports basic and applied biomedical research designed to advance...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- Federal Grant Award Summary Children's Research Institute received a $777,659 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award supports research titled "Use of ProResolution and Restorative Pharmacology Approaches for DMD Therapy," focusing on the development of innovative therapeutic interventions for Duchenne muscular dystrophy (DMD). The...
- Federal Grant Award Summary The University of Washington received a $1,697,415 Project Grant award dated May 1, 2026, from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The award supports research and development of low-volume resuscitants for burn treatment in austere conditions, a project designated "RADIANT STAR." Research will be conducted at the University of Washington's Seattle campus through April 30, 2029, leveraging...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
- Federal Grant Award Summary The Washington University was awarded $500,000 in Project Grant funding from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025 through July 31, 2027. The award supports research titled "Harnessing Single-Cell T Cell-Receptor Sequencing to Accelerate Diagnosis in Inflammatory Arthritis," to be conducted at the university's University City, Missouri campus. This research project...
- This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $572,306 in funding to the University of Washington for a 3-year research project to develop "ENHANCED GENE THERAPY FOR DMD USING LARGER DYSTROPHINS AND LOWER VECTOR DOSES". The aim is to advance gene therapy approaches for treating Duchenne muscular dystrophy (DMD) by utilizing larger dystrophin gene constructs and reducing the required vector doses. The...